Oruka Therapeutics (ORKA) Invested Capital (2010 - 2026)
Oruka Therapeutics' quarterly Invested Capital came in at $486.7 million in Q1 2026, up 33.45% year-on-year from $364.7 million in Q1 2025, and up 3.13% quarter-over-quarter from $471.9 million in Q4 2025.
Oruka Therapeutics has reported Invested Capital for 17 years, with the latest figure at $486.7 million in Q1 2026.
- For the quarter ending Q1 2026, Invested Capital rose 33.45% year-over-year to $486.7 million; the trailing twelve-month figure through Mar 2026 stood at $486.7 million (up 33.45% YoY), and the FY2025 full-year result was $471.9 million, up 23.47% from the prior year.
- Invested Capital for Q1 2026 stood at $486.7 million, up from $471.9 million in the prior quarter.
- The five-year high for Invested Capital was $486.8 million in Q3 2025, with the low at -$29.0 million in Q2 2024.
- Average Invested Capital over 5 years is $186.7 million, with a median of $45.0 million recorded in 2022.
- Year-over-year, Invested Capital plunged 173.86% in 2024 and soared 5266.81% in 2025.
- Tracing ORKA's Invested Capital over 5 years: stood at $41.7 million in 2022, then decreased by 11.17% to $37.0 million in 2023, then jumped by 932.47% to $382.2 million in 2024, then grew by 23.47% to $471.9 million in 2025, then advanced by 3.13% to $486.7 million in 2026.
- The last three Invested Capital figures came in at $486.7 million (Q1 2026), $471.9 million (Q4 2025), and $486.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 595,226.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.96 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - | 486.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 486.72 Mn |
| Dec 31, 2025 | 471.93 Mn |
| Sep 30, 2025 | 486.79 Mn |
| Jun 30, 2025 | 343.64 Mn |
| Mar 31, 2025 | 364.73 Mn |
| Dec 31, 2024 | 382.22 Mn |
| Sep 30, 2024 | 342.37 Mn |
| Jun 30, 2024 | -28.98 Mn |
| Mar 31, 2024 | -7.06 Mn |
| Dec 31, 2023 | 37.02 Mn |
| Sep 30, 2023 | 37.97 Mn |
| Jun 30, 2023 | 39.24 Mn |
| Mar 31, 2023 | 40.53 Mn |
| Dec 31, 2022 | 41.67 Mn |
| Sep 30, 2022 | 42.73 Mn |
| Jun 30, 2022 | 44.96 Mn |
| Mar 31, 2022 | 47.94 Mn |
| Dec 31, 2021 | 51.04 Mn |
| Sep 30, 2021 | 56.60 Mn |
| Jun 30, 2021 | 61.21 Mn |
| Mar 31, 2021 | 65.91 Mn |
| Dec 31, 2020 | 46.52 Mn |
| Sep 30, 2020 | 50.46 Mn |
| Jun 30, 2020 | 10.31 Mn |
| Mar 31, 2020 | 6.31 Mn |
| Dec 31, 2019 | 7.61 Mn |
| Sep 30, 2019 | 8.80 Mn |
| Jun 30, 2019 | 9.19 Mn |
| Mar 31, 2019 | 7.32 Mn |
| Dec 31, 2018 | 6.03 Mn |
| Sep 30, 2018 | 7.46 Mn |
| Jun 30, 2018 | 9.00 Mn |
| Mar 31, 2018 | 11.05 Mn |
| Dec 31, 2017 | 10.28 Mn |
| Sep 30, 2017 | 14.35 Mn |
| Jun 30, 2017 | 14.75 Mn |
| Mar 31, 2017 | 18.04 Mn |
| Dec 31, 2016 | 22.19 Mn |
| Sep 30, 2016 | 26.48 Mn |
| Jun 30, 2016 | 30.89 Mn |
| Mar 31, 2016 | 34.58 Mn |
| Dec 31, 2015 | 38.07 Mn |
| Sep 30, 2015 | 41.09 Mn |
| Jun 30, 2015 | 43.76 Mn |
| Mar 31, 2015 | 12.13 Mn |
| Dec 31, 2014 | 14.74 Mn |
| Sep 30, 2014 | 17.20 Mn |
| Jun 30, 2014 | 19.32 Mn |
| Mar 31, 2014 | 21.53 Mn |
| Dec 31, 2013 | 15.58 Mn |
| Sep 30, 2013 | 18.37 Mn |
| Jun 30, 2013 | 20.03 Mn |
| Mar 31, 2013 | 3.31 Mn |
| Dec 31, 2012 | 2.91 Mn |
| Sep 30, 2012 | 3.18 Mn |
| Jun 30, 2012 | 3.29 Mn |
| Mar 31, 2012 | 4.36 Mn |
| Dec 31, 2011 | 5.73 Mn |
| Sep 30, 2011 | 5.73 Mn |
| Jun 30, 2011 | 7.55 Mn |
| Dec 31, 2010 | 6.77 Mn |